Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04662255
Title Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)
Acronym BRUIN-MCL-321
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Loxo Oncology, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS


No variant requirements are available.